References
  1. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215-35.
  2. Trapnell BC, Whirsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003 Dec 25;349(26):2527-39
  3. Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol. 2010 May; 135(2): 223-235
  4. Suzuki T. Trapnell BC. Pulmonary alveolar proteinosis syndrome. Clin Chest Med. 2016 Sep:37(3): 431-440
  5. Kavuru MS, Bonfield TL, Thompson MJ. Pulmonary alveolar proteinosis. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA, editors. Textbook of pulmonary medicine, 4th ed. Philadelphia: Elsevier; 2006. pp. 1716–1734.
  6. Whitsett JA, Wert SE, Trapnell BC. Genetic disorders influencing lung formation and function at birth. Hum Mol Genet 2004;13:R207–R215
  7. McCarthy C, Avetisyan R, Carey BC, et al. Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2018;13 (1):129
  8. Inoue Y, Trapnell BC, Tazawa R. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis is Japan. Am J Respir Crit Care Med. 2008 Apr 1;177(7):752-62.
  9. Trapnell BC, Luisetti M. Pulmonary Alveolar Proteinosis Syndrome. Murray and Nadel’s Textbook of Respiratory Medicine, sixth edition (2016). Elsevier. PP:1260-1274
Figure 1. CT chest showed crazy paving consistent with PAP.
Figure 2. The 3-liter canisters (total of 18L) that used for WLL. The one on the far right is the product of the first wash, which gradually becomes clear as lavage continues. The one on the far left is the product of the last wash.
Table 1 . This table shows the trend of pulmonary function tests in the patient.